The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing. 

Taking place at the University Hospital Basel (UHB), this Phase 1 investigator-initiated study seeks to understand how substances similar to MDMA, particularly MDA, Lys-MDMA and Lys-MDA work on people that don’t have a mental health diagnosis.

The 18-month trial will divide the cohort between groups that will be given the drugs and a placebo group, and compare results through pharmacokinetics and psychological and psychometric tests.

More specifically, the randomized, placebo-controlled, double-blind, fiveperiod crossover study will enroll 24 healthy subjects …

Full story available on